Thomas Beale
Senior Director, CMC Early Phase, RLT, Eli Lilly and Company
Peptide Radiopharmaceutical Panel
Abstract
Eli Lilly and Company was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products.
Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 95 countries.
Bio
Thomas (Tom) Beale is currently a Senior Director, CMC Early Phase, RLT at Eli Lilly and Company, with oversight of internal and external precursor development, isotope supply and translational radiochemistry functions to deliver radioligand therapies (RLTs) from candidate identification to clinical studies. He joined Lilly as part of the POINT Biopharma acquisition in 2024, where he was previously responsible for precursor development for early and late stage programs.
Prior to joining POINT, he worked in traditional API development and scale-up as part of Alphora Research (now Eurofins CDMO Alphora) for ~8 years, starting as a bench chemist and eventually having technical leadership of multiple parallel process development programs, from IND-enabling to PPQ and commercial stages with a team of >10 chemists. Overall, he has contributed to >15 IND or equivalent submissions and a number of NDA submissions.
Before starting in industry, Tom completed postdoctoral studies at the University of Toronto in the group of Prof. Mark Taylor, working on methodologies for regioselective glycosylations using boron catalysis with partial support from the Heart and Stroke Foundation. His graduate studies in organic chemistry were performed in the group of Prof. Steve Ley at the University of Cambridge with funding from Cancer Research UK, and his Master's was obtained in Chemistry from Imperial College, London.